Notícias e Destaques The Myeloma Matrix Part II (Phase I -> Phase I/II)

The Myeloma Matrix Part II (Phase I -> Phase I/II)
4.17.07

The IMF is committed to providing a total overview of the "future" as well as the current state of myeloma treatments. The printed version of the Myeloma Matrix provides updated information about drugs beginning with pre-clinical developments, tracks drugs as they proceed through Phases I – III of clinical trials, and provides information on trials that are being conducted by NCI-sponsored cooperative groups as well as other myeloma study groups. Call the toll-free hotline (800) 452-2873 for your printed copy.

PHASE
BRAND NAME
(OTHER NAME)
COMPANY
(SPONSOR)
INDICATION
Phase I/II
Actimid™
(CC-4047)
Celgene Corporation Immunomodulatory agent for relapsed/refractory myeloma. Trials only in UK.
Amplimexon
(imexon)
AmpliMed Corp. Rapamycin analog administered IV.
AVN944 Avalon Pharmaceuticals Open-label, repeat-dose escalation, safety and tolerability trial for patients with advanced hematological malignancies.
BrevaRex® AltaRex Trials planned for monoclonal antibody against MUC1 antigen.
Brostallicin
(PNU-166196)
Pharmacia and NCI For the treatment of recurrent or refractory multiple myeloma.
CERA
(Continuous
Erythropoiesis
Receptor
Activator)
Roche Indication: treatment of cancer-related anemia
CNTO 328 Centocor Monoclonal antibody to IL-6
Curcumin
(diferuloyl-
methane)
MD Anderson CC Present in turmeric and yellow mustard, inhibits NF-kappaB.
Defibrotide
Gentium S.p.A. Used as a MM cell sensitizer in combination with melphalan, prednisone, thalidomide as salvage treatment in advanced myeloma.
GCS-100LE GlycoGenesys, Inc. Dose-escalation study of polysaccharide-based (carbohydrate) agent for relapsed/refractory myeloma.
hLL1
(anti-CD74
mAb; IMMU 115)
Immunomedics
Open-label, multi-center study of a humanized monoclonal antibody to the CD74 myeloma cell surface antigen for patients with recurrent or refractory multiple myeloma who have failed at least 2 prior standard systemic treatments
Idiotypic
vaccination
+ miniallo-
transplant
University Clinic of Navarre
Pamplona, Spain
Patients (either newly-diagnosed or in partial response following autologous transplantation) with HLA full-matched, sibling donor.
Quadramet
(samarium
Sm-153
lexidronam)
Cytogen Corporation For the treatment of bone pain associated with metastatic bone disease in patients with recurrent or refractory myeloma.
Stemgen Amgen Tested abroad as stem cell booster; protocols pending in US.
TacI-Ig ZymoGenetics Fusion protein given to patients with relapsed/refractory myeloma
Trisenox™
(arsenic
trioxide
injection)
Cephalon Oncology With vitamin C for relapsed and refractory multiple myeloma.
VELCADE®
(bortezomib,
PS-341,
LDP-341,
MLN-341)
Millennium Pharmaceuticals With Adriamycin and dex as front-line therapy. (UK only)
VELCADE®
(bortezomib,
PS-341,
LDP-341,
MLN-341)
Millennium Pharmaceuticals As maintenance therapy after auto-transplant in patients with intermediate or advanced MM.
VQD-001
(sodium stibogluconate, SSG)
VioQuest Pharmaceuticals, Inc. Targeted to protein tyrosine phosphatases; safety, efficacy, and tolerability trial for solid tumors, lymphoma, and myeloma.
ZIO-101
ZIOPHARM, Inc. Multi-center trial of small-molecule organic arsenic
Phase I
1D09C3 GPC Biotech Anti-major histocompatibility complex (MHC) class II monclonal antibody that has received orphan medicinal product designation for the treatment of myeloma by the European Medicines Agency.
Allomune System BioTransplant To facilitate acceptance of donor stem cells.
anti-IGF-1R
mAb
(CP-571,871);
monoclonal
antibody to
insulin-like
growth factor
-1 receptor)
Pfizer Relapsed and refractory MM.
ATN-224
Attenuon, LLC
Oral dose-escalation study for patients with advanced hematologic malignancies.
BB-10901
(
huN901-DM1
huN901-N2'-
Deacetyl-N2"-(3-
Mercapto-1-
oxopropyl)-
Maytasine)
ImmunoGen , Inc. Targets and kills cancer cells that express the CD 56 antigen. A humanized monoclonal antibody coupled with a cancer-killing agent.
Campath-1H
(alemtuzumab,
monoclonal
antibody CD52)
National Cancer Institute and Fred Hutchinson Cancer Research Institute Used before mismatched allo transplant to prevent GVHD.
CNTO 328
Centocor
Chimeric antibody to Interleukin-6 for patients with MM, NHL, or Castleman’s Disease
CHIR-258
Chiron Fibroblast growth factor receptor 3 inhibitor for potential treatment of t(4;14) MM
dendritic
cell vaccine
Rockefeller University Hospital
Autologous dendritic cells pulsed with alpha-galactosyl ceramide for patients with perisistent or relapsed MM after initial therapy
ENMD 0995
(analog S-3APG)
EntreMed Thalidomide analog.
fenretinide
(4-HPR)
California Cancer Consortium; NCI
Intravenous chemotherapy agent in a safety and tolerability study for patients with relapsed or refractory hematologic cancer
fluphenazine
Immune Control Inc.
Serotonin antagonist for relapsed/refractory mm.
HCD122
(CHIR-12.12)
Novartis and
Xoma Ltd.
Monoclonal antibody to CD40
IPI-504
Infinity Pharmaceuticals
Safety and efficacy trial of Heat Shock Protein 90 inhibitor on patients with relapsed/refractory mm.
KOS-953
(tanespimycin);
17-allylamino-
17-demethoxy-
geldanamycin)
Kosan Biosciences Inhibitor of heat shock protein 90 being evaluated both as monotherapy and in combination with VELCADE for patients with relapsed, refractory multiple myeloma.
LymphoRad® 131
(Radiolabeled
BLyS Protein)
Human Genome Sciences Iodine-labeled B lymphocyte stimulator.
MAGE-A3 and
NY-ESO-1 (peptide
vaccination)
University of Arkansa and Celgene Corp. Subcutaneous peptide vaccination in combination with DT-PACE and autotransplant.
Measles Virus
(Oncolytic Measles Virus)
Mayo Clinic Engineering the virus to make it more "user-friendly" as an agent for cancer therapy
MRA (humanized
anti-human IL-6
receptor MAb)
Chugai Pharma USA
Safety and efficacy study of monoclonal antibody to IL-6 in patients with myeloma.
MS-275 Berlex Labs For poor-risk hematologic malignancy.
Myelovax Apalexo Biotechnologie GmbH For treatment of multiple myeloma.
NPI-0052
(salinos-
poramide)
Nereus Pharmaceuticals
A single-agent, dose escalation study for patients with relapsed or relapsed/refractory multiple myeloma. Sites: Dana- Farber Cancer Institute, Ohio State University, Roswell Park Cancer Institute and University of Chicago.
Palifermin Amgen, Inc. Supportive care to help prevent mucositis after HDT.
PR-171
(carfilzomib)
Proteolix
Safety and dose limiting tolerance trial of a novel proteasome inhibitor for patients with hematologic malignancies
Product R Advanced Viral Research Corp. For treatment of cachexia in patients with hematopoietic cancers, including MM.
Pyroxamide National Cancer Institute Histone deacytelase (HDAC) inhibitor for advanced malignancies.
Revlimid®
(CC-5013,
lenalidomide)
Celgene Corporation Combined with Doxil, vincristine, and dexamethasone (Dvd) in relapsed/refractory MM.
Revlimid®
(CC-5013,
lenalidomide)
Celgene Corporation Single-center study of Revlimid in combination with Velcade for relapsed/refractory MM.
RTA 402
(CDDO-Me)
Reata Pharmaceuticals, Inc.
Oral NF-kappa B inhibitor being tested for safety and efficacy in patients with solid tumors, lymphoma, and myeloma.
SAHA
(suberoylanilide
hydroxamic acid,
SW 064652)
Aton Pharma, Inc. Histone deacytelase (HDAC) inhibitor for advanced myeloma
SGN-40 Seattle Genetics Monoclonal antibody to CD40 protein on myeloma cell surface.
SNS-032 Sunesis Dose-excalation study to examine the safety and tolerability, as well as preliminary anti-tumor activity, of a novel targeted inhibitor of CDKs 2, 7 and 9, in patients with B-cell malignancies.
Th2 Cells National Cancer Institute For prevention of GVHD following mini allogeneic transplant.
Thalomid®*
(thalidomide)
Arkansas Cancer Research Center Used in combination with VELCADE for refractory multiple myeloma.
TKI-258
Novartis
A novel, multitargeted tyrosine kinase inhibitor for the treatment of relapsed/refractory multiple myeloma.
TPA
(12-O-tetradeca-
noylphorbol-13-
acetate)
Cancer Institute of New Jersey and NCI Chemotherapy agent for treatment of relapsed/refractory hematologic malignancies.
Triapine®
(3-Aminopyridine
-2-
carboxaldehyde
Thiosemi-
carbazone)
Vion DNA synthesis inhibitor combined with cytarabine in hematologic malignancies.
Trisenox™
(arsenic
trioxide
injection)
Cephalon Oncology Apoptosis inducer for relapse.
VELCADE®
(bortezomib,
PS-341,
LDP-341,
MLN-341)
Millennium Pharmaceuticals, Inc. Trials combining VELCADE® with other agents in relapse setting. See complete list of VELCADE® trials.
VNP40101M Vion Novel alkylating agent in combination with cytarabine for patients with hematologic malignancies.
VQD-001,
SSG, stibogluconate
VioQuest Pharmaceuticals, Inc. Targets protein tyrosine phosphatases. Trial is open at the Cleveland Clinic Cancer Center to examine the effectiveness, safety, and tolerability of SSG for the treatment of solid tumors, lymphoma, and myeloma.
Zolinza (vorinostat, SAHA)
Merck
HDAC inhibitor that has already been approved for cutaneous T-Cell lymphoma and is now being studied in myeloma in combination with bortezomib (Velcade).
The Myeloma Matrix is brought to you in part
by grants from
Millennium Pharmaceuticals, Celgene Corporation,
and Ortho Biotech.
© 2005-2006 The International Myeloma Foundation

<< Back to The Myeloma Matrix Part I (Phase II to FDA Approved)